Tenaya Therapeutics (TNYA) Cash & Equivalents (2020 - 2026)

Tenaya Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $80.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 50.43% year-over-year to $80.9 million; the trailing twelve-month figure through Mar 2026 stood at $80.9 million (up 50.43% YoY), and the FY2025 full-year result was $100.5 million, up 2225.86% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $80.9 million, down from $100.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $100.5 million in Q4 2025, with the low at $4.3 million in Q4 2024.
• Average Cash & Equivalents over 5 years is $56.2 million, with a median of $58.1 million recorded in 2024.
• Year-over-year, Cash & Equivalents slumped 90.54% in 2024 and soared 2225.86% in 2025.
• Tracing TNYA's Cash & Equivalents over 5 years: stood at $95.3 million in 2022, then slumped by 52.05% to $45.7 million in 2023, then tumbled by 90.54% to $4.3 million in 2024, then soared by 2225.86% to $100.5 million in 2025, then fell by 19.55% to $80.9 million in 2026.
• The last three Cash & Equivalents figures came in at $80.9 million (Q1 2026), $100.5 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.

Peer Comparison